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Abstract 
Nanotechnology is widely used in many aspects of the design and manufacture of medical devices. To 
date, many of these new medical devices, referred to as nano medical devices, have been submitted to 
health authorities for premarket regulatory review. There are ongoing discussions between medical device 
manufacturers and regulatory authorities regarding the standards and methods required for the 
evaluation process. Taking into consideration aspects including nano-toxicology and biocompatibility, the 
clinical effects of nanotechnology and risk management, there are issues yet to be resolved. In this article, 
we will discuss nano medical device safety from the regulatory control point of view. 
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1. Introduction 
There is no single official definition of nanotechnology in the application of medical use, but the US FDA 
refers to nanotechnology as engineered materials or end products or the exhibition of properties or 
phenomena that are attributable to at least one of the dimensions in the range of 1 to 100 nanometers in 
general [1]. Due to these dimensions, the physical and chemical, and thereby the biological properties of 
these materials may not necessarily be the same as the same material in the bulk configuration.  
The use of nanomaterial has been successfully explored in many areas such as chemical materials, 
electronics, IT and the biomedical industry. In Taiwan, nano-products are becoming more and more 
common in the domestic market, including nano-rags, nano-clothing, nano-silver deodorant liquids, 
ceramic nano-energy cups, nano-toilets, etc. The advertising of these products infers that they are better 
than their traditional counterparts with additional benefits from nanotechnology. It seems that all products 
designated as "nano" will offer some sort of magical and, more importantly, beneficial effects. 
Consequently, the Ministry of Economic Affairs of Taiwan has commissioned the Center for Measurement 
Standards of the Industrial Technology Research Institute (ITRI) to assess and verify the specifications of 
nano products. A “Nanomark” will be granted to those nano products that meet these criteria. The 
purpose of this assessment is to ensure that products issued with the “Nanomark” do in fact possess 
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certain pre-defined nanotechnology characteristics and scientific evidence to support claims regarding 
pollution control, antibacterial activity, deodorant properties, wear-resistance and other characteristics as 
described in the product specification, in order to protect the interests of consumers.  
With regard to nano medical devices (medical devices that involve the use of nanomaterials or 
nanotechnology in general), safety and efficacy are of paramount importance. It is necessary to point out 
that any medical device, in particular those that employ novel technology like nanotechnology in which the 
toxicity of nanomaterials is not yet fully understand or there is little history of a comprehensive evaluation 
of the technology, their performance and safety should be properly evaluated.  It is for this reason that 
nano medical devices have raised the regulatory concerns of the health authorities regarding safety and 
efficacy. For example, nano-fiber socks that are advertised as possessing antibacterial, deodorant and 
other functions can attract the attention of customers and increase the selling price of the product. 
However, the use of such products for medical purposes has garnered the attention from the health 
authorities, resulting in additional safety assessments on the nanomaterial used before granting marketing 
authorization. In this context, it is crucial to ensure that the nanomaterial creates no new hazards to 
human health or the environment compared with the traditional product, and the product offers the 
features depicted in the specifications. For that, functions such as antibacterial and deodorant activity may 
not seem critical compared with a safety evaluation. The situation is further complicated by developments 
in nanotechnology, whereby nanotechnology applications in different disciplines are integrated into a 
single purpose, like combination products that combine any two or even three of nanotechnology utilizing 
medical devices, drugs and biologics, making product classification difficult. Consequently, the product 
review can be problematic. A systematic and multi-disciplinary approach is therefore necessary, and 
particular attention should be paid during the regulatory review of these products.  
2. Medical applications of nanotechnology  
Nanomedicine generally refers to the clinical application of nanotechnology to provide a novel therapy 
or diagnosis, including diagnostic equipment, drug delivery devices, gene therapy and tissue engineering. In 
2003, Miller recommends the definition of nanomedicine as "the monitoring, repair, construction and 
control of human biological systems at the molecular level, using engineered nanodevices and 
nanostructures" [2]. As nanotechnology manipulates nanostructures at the molecular level, it could 
potentially generate substantial changes in properties such as the melting point, electrical, magnetic, 
optical or surface properties and chemical activity and thereby have an impact on the biological properties 
within a limited space. These modifications could make products that are not just smaller but also lighter, 
more flexible, mechanically stronger, more sensitive, more selective or more efficient.  
The regulatory control of nano medical devices should consider the product’s safety, efficacy and 
quality. The safety of nano products is of particular importance, especially when in contact with the surface 
of the human body. Additionally, it is unclear whether or how the absorption and distribution of 
nanomaterials in the human body would introduce new risks. With regard to product efficacy, the 
manufacturer should determine the material’s size, shape, structure and distribution to ensure that the 
nanomaterial reaches the nanoscale, resulting in the predetermined and desired new properties, features 
or enhancements. In terms of quality, manufacturers should pay attention to validation, verification, uses 
and manufacturing processes in relation to the nanomaterial. To sum up, the important issues related to 
the regulatory control of nano medical devices include the definition of the nano medical device, 
classification, premarket approval procedures, good manufacturing practices, labeling and postmarket 
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surveillance. In view of the complexity of the technology involved, it will be a challenge to establish a 
regulatory requirement and procedure to control nano medical devices, whether it is a nano medical 
device used on its own or in combination with other equipment or drugs. Ultimately, the aim of regulatory 
authorities is to ensure that the product offers improved treatment to the benefit of patients without 
incurring unacceptable risk.  
There are already a variety of nano medical devices that have been allowed onto the market by the US 
FDA [3]. Generally, these products serve the same clinical purpose as the related traditional medical device. 
However, the incorporation of a nanomaterial improves its effectiveness, performance or functionality, 
such as in antimicrobial dressings, dental materials, orthopedic materials like bone cement, and in vitro 
diagnostic reagents [3]. It is the FDA’s current thinking that regulations can only be based on the current 
best information, and the product has to be fundamentally safe and effective, independent of whether the 
product employs a nanomaterial [4-5]. The product should, therefore, comply with the basic, relevant 
premarket review procedure and registration regulations and, if necessary, comply with relevant 
nanotechnology evaluations like toxicology assessments. 
The assessment of the safety and effectiveness of nano medical device is very much an ongoing 
development process for health authorities as well as academia in many countries. In fact, many nano 
medical devices that are currently on the market were approved through the conventional medical device 
approval procedure without taken full consideration of the presence of the nanomaterial. Having said that, 
some health authorities are becoming more aware that the traditional assessment approach may not be 
fully appropriate for nano medical devices, particularly in terms of assessing the risk associated with the 
nanomaterial. Recent animal studies have also demonstrated that nanomaterials exhibit many unique 
toxicological properties. Therefore, in contrast with traditional products, nano medical devices require 
more careful consideration in the safety assessment and the development of a standardized evaluation 
protocol. 
In Taiwan, the Ministry of Health has expressed a high degree of concern regarding the regulatory 
control of nano medical devices, and is looking into the relevant regulatory procedures for control nano 
medical devices. Future regulations for nano medical devices may include a pre-market review, quality 
management systems and post-market surveillance.  Of those topics, there are issues of particular interest, 
including risk management, safety and efficacy assessments, nano process validation, labeling and warning, 
adverse event reporting and recall, and monitoring. The risk assessment of the effects of nanomaterials on 
public health should be a long-term, evolving process. It is important to maintain communication with 
experts in the area to ensure the speedy exchange of information, and to plan and adjust the risk 
assessment/management procedure accordingly. At the moment, although the international community 
does not regard the development of new legislation for nano medical devices as being necessary, it is 
important to pay close attention to the development of any international standards in order to formulate 
or adjust the relevant review mechanisms. 
3. Risk assessment for nanomaterials 
For the regulatory control of nano medical devices, in addition to regulations and product pre-market 
review mechanisms, risk management forms the basis of nano medical device assessment and the 
establishment of nano medical device regulations. For many nano medical devices, there is a fine balance 
between risk and effectiveness, especially in the medical field where nanomaterials are emerging as a 
promising approach for diagnostic technology and new treatment modalities [6]. In contrast to bulk 
ADMET & DMPK 1(4) (2013) 76-81 Nanomaterials safety 
doi: 10.5599/admet.1.4.19 79 
materials, nanomaterials can exhibit very different physical, chemical and biological properties that differ 
from expectation, which could result in new risks that need proper evaluation and even control before 
marketing is permitted. 
There is currently no specific standard for risk management regarding nano medical devices; however, 
the international standard ISO 14971 (Medical devices – Application of risk management to medical 
devices) could be used for this purpose. Like traditional medical devices, the existing standard operating 
procedures can be used, with special attention paid to potential hazards related to the properties and 
phenomena that can result from the nanomaterial or nanostructure. These potential hazards should be 
first identified, estimated and evaluated according to the predefined risk acceptance criteria. If necessary, 
risk control measures should be implemented, thereby ultimately ensuring that the product’s benefits 
outweigh the risk [7]. The Identification of nano-hazards requires in-depth and in some cases multi-
disciplinary knowledge of the product’s technology, application environment, regulatory requirements and 
even usability. Nano medical devices may on first appearance look exactly the same as their traditional 
counterparts, but for this exact reason, their usability becomes very important and the use hazards should 
be properly evaluated if necessary, as usage error may result from failure to tell the nano device from the 
traditional product. The use of standards like ISO/IEC 62366 [8] and ANSI/AAMI HE75 [9] are just some of 
the best currently available tools to address the usability issue. The identification of hazards can be 
performed systematically according to the different characteristics of the nanomaterial. For a nanomaterial 
with a novel structure, the hazards are usually more difficult to predict (as compared with a micronized 
material such as metal oxide, titanium dioxide or zinc oxide). In cases where these nanomaterials are 
enclosed within a surface coating or matrix material, the biological reactivity and mobility will be 
contained. However, the durability of the enclosure would then need to be considered in order to avoid 
the unexpected leaching of these nanomaterials into the environment. 
Toxicology is obviously a major risk of nanotechnology that needs to be addressed. Nanotoxicology risks 
are still very much debatable issues, and most result from various pathways of adsorption into the body. 
Therefore, a nanomaterial unexpectedly or uncontrollably entering the human body through the skin or by 
inhalation is a concern. Research studies have shown that as a material’s particle size becomes smaller, the 
total surface area of the potentially inhaled or adsorbed particles becomes greater, leading to increased 
toxicity [10]. Airborne nanomaterials are often the main culprit in terms of toxicity.  In order to assess the 
effects of exposure, adsorption, transport and distribution within the human body, various factors need to 
be taken into consideration, including the particle concentration in air, particle size, shape, surface area 
and surface chemistry. 
4. Nano-toxicology 
Some types of nanomaterials may be harmful to humans. They can be classified into the following two 
kinds of nanomaterial structure: 
1. Free form nanoparticles: this refers to the direct use of nanoparticles in the manufacturing process. 
This usually consists of a single element, compound or complex mixture type that can be released 
into water and air or accumulate in soil. 
2. Fixed form nanoparticles or nanocomposites: this refers to a nanomaterial that becomes part of a 
product, which may be nanocomposites or nano surface structures.  
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Compared to fixed nanoparticles, it is imperative to explore the possibility that free nanoparticles could 
be harmful. Since nanomaterials are quite different from the original material, the related toxicity is 
expected to be unlike that of the original material.  Generally, it is difficult to obtain a uniform particle size 
distribution (monodisperse) in a nanoparticle formulation. In the absence of a stabilizing agent, 
nanoparticle aggregation is likely to occur, which could deteriorate the properties of the product and 
introduce complications in particle size characterization. Some nanomaterials, such as carbon nanotubes 
and metal oxides, tend to form clusters [10-11]. A larger particle size could potentially reduce membrane 
permeability and discourage dispersion throughout the human body, such as in the respiratory tract [11-
12].  
There are four ways that nanoparticles can enter the human body: through the skin, by inhalation, oral 
ingestion or during a medical procedure (e.g. release from implants). Exposure assessments are used to 
evaluate the risk of human in contact with the nanoparticle product. This should include the whole life 
cycle of the product starting from synthesis to disposal. Although the main concerns are the hazard to the 
customer during product usage, assessments should also be done after disposal to evaluate nanoparticle 
release into the environment. Furthermore, the manufacturing staff remains the most likely population to 
be exposed to nanoparticles, and should be properly evaluated during risk management. The nanoparticle 
exposure assessment could vary between different products, and should depend on the product design to 
assess any potential risks. 
The dimensions of the nanomaterial affect its toxicity. For nanoparticles, smaller particles are usually 
more active and potentially more toxic. Moreover, one should take into account the shape factor. The 
human immune system is poorly defensive against nanoparticles, and does not recognize nanoparticles. 
For instance, the defense mechanism in the lung cannot deal with nanoparticles less than 70 nm in size 
[6,13]. Nanoparticles less than 50 nm in size can easily enter and move into the nucleus of human cells, and 
30 nm particles may damage the central nervous system [6,13]. 
It is evident that nanomaterial research and risk assessments are urgently needed to clarify the 
potential effects of these materials on humans, particularly in terms of cardiovascular, carcinogenic, 
reproductive, developmental, immunological and neurological aspects. Although there are still many 
uncertainties and limitations in the current understanding of nanomaterials, it is essential to conduct risk 
assessments on nanomaterials and nano medical devices before the product is allowed to be marketed. 
5. Conclusions 
In view of rapid advancements in the field of nanotechnology, it is very challenging to come up with a 
set of nano medical device regulations that can cover all the relevant issues. For currently listed nano 
medical products, such as those containing nano silver antimicrobial dressings, the FDA review process has 
been completed. This will serve as a classic example for the regulatory regulations on a nano medical 
device. However, it is questionable whether such an example can be directly extended to other kinds of 
nano medical devices because the risk and benefit factors are likely to be very different. For instance, 
nanoparticle drug delivery systems that work by targeting tumors and nano silver antimicrobial dressing 
products are based on completely different scientific principles. Nevertheless, it is mandatory for the 
manufacture of nano medical devices to meet quality, testing and safety and other regulations in order to 
protect the manufacturing staff, customers and end users. Equally important, device manufacturers are 
also required to submit product development, testing and registration applications with other related 
information to the relevant regulatory body for proper evaluation. Because of the diversity of 
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nanomaterials that can be applied to medical devices, regulatory regulations are important, and frequent 
updates are needed to keep pace with rapidly emerging applications. 
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